We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns New Jersey Compounder for Sterility, Repackaging Violations
FDA Warns New Jersey Compounder for Sterility, Repackaging Violations
The FDA issued a warning letter to New Jersey drug compounder Ideal Specialty Apothecary citing “serious deficiencies” in its sterile drug production and for repackaging a cancer drug without a license.